The Neglected Global Diseases Initiative welcomes faculty members from any discipline. We welcome affiliated members from other universities or organizations.
Professor of Parasitology, Liverpool School of Tropical Medicine
Adjunct Lecturer, New York University
Phone: 604.263.4490 / 212.860.4427
Trained as a health behavioral scientist and specialized in cancer epidemiology, Dr. Keiko Honda has focused her research on cultural, psychosocial, and behavioral processes that affect health outcomes, psychological well-being, and adjustment to chronic illness among ethnic minorities, as well as health disparities between immigrants and non-immigrant whites. She is carrying this work forward by developing a systematic and comprehensive exploration of the psychosocial-behavioral links that underlie adaptive responses across the spectrum of disease threat and disease prevention.
Intel Therapeutics Inc.
Indel Therapeutics Inc. is a biopharmaceutical company dedicated to developing new drugs to address the global health crisis caused by antibiotic resistance.
Professor | Faculty of Health Sciences
Simon Fraser University
Dr. Hogg is identifying ongoing health inequities among vulnerable HIV-positive populations in British Columbia and the rest of Canada. Hogg and his research team will investigate three key areas in HIV care and the accessibility of HIV treatment. They will study how optimism influences current sexual behavior and new infection rates among gay, bisexual and other men who have sex with men. Such optimism stems from the availability of highly active antiretroviral therapy (HAART), an effective treatment strategy to combat HIV/AIDS. Hogg is a senior scientist in the Epidemiology and Population Health program at the BC Centre for Excellence in HIV/AIDS (BC-CfE) and is also principal investigator of the Canadian HIV Observational Cohort (CANOC) Collaborative Research Centre.
Hon. Keith Martin MD, Fmr MP
Mahidol Oxford Tropical Medicine Research Unit
Adjunctive therapy for severe malaria treatment
Severe malaria caused by Plasmodium falciparum involves a spectrum of intravascular hemolysis where cell-free haemoglobin increases with disease severity. Fulminant hemolysis, manifesting as blackwater fever, is associated with kidney dysfunction in up to 64% of patients. Hemoglobin released from red blood cells during hemolysis can cause severe oxidative damage and kidney injury as a result of hemoglobin-induced oxidation of lipids. Recent studies show that acetaminophen inhibits hemoprotein-induced lipid peroxidation, resulting in decreased oxidative kidney injury, and improved renal function. We hypothesize that acetaminophen will reduce kidney injury in patients with severe falciparum malaria by inhibiting hemoglobin-induced lipid peroxidation. The main activity proposed is a randomized open label controlled trial of acetaminophen in patients with severe falciparum malaria to assess its modulating effect on renal function and oxidative stress.
The study can be located at: https://clinicaltrials.gov/ct2/show/NCT01641289?term=NCT01641289&rank=1